Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of scutellarin

A technology of scutellarin and scutellarin, which is applied in the field of new application of scutellarin aglycon, can solve the problem of high incidence and aggravation of rhabdomyolysis in patients that have not been reported on scutellarin aglycon and its derivatives. Potassium and other problems to achieve the effect of improving blood perfusion, reducing proteinuria, and improving pathological changes

Inactive Publication Date: 2015-09-30
KPC PHARM INC
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

(2) Control hyperlipidemia and hypercholesterolemia: taking statin lipid-lowering drugs (such as pravastatin, lovastatin, simvastatin, atorvastatin), but it can lead to a higher incidence of rhabdomyolysis in patients ; Taking ACE inhibitors reduces proteinuria and hyperlipidemia, but may exacerbate hyperkalemia in patients with moderate to severe renal insufficiency
(3) Regulating electrolytes: Thiazides or loop diuretics can be used, but they may impair renal function and easily lead to thrombosis
(4) Corresponding treatment of hypertension: ACE inhibitors and ACE receptor antagonists are used in combination, but thrombosis often occurs
But at present, there is no report on the application of scutellarin aglycone and its derivatives in anti-nephritis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of scutellarin
  • New application of scutellarin
  • New application of scutellarin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] After modeling, the eating and activity status of the rats were observed every day, and the body weight was weighed once a day. The results are shown in Table 1:

[0059] Table 1: Body weight changes of model rats

[0060]

[0061] Compared with the control group: ▲ / ▲▲P<0.05 / 0.01

[0062] As can be seen from Table 1, before the administration, the basal body weight of the animals in each model group had no significant difference compared with the normal control group; at the end of the administration, except for the obvious increase in the weight of the animals in the normal control group, the body weight of the other groups increased slowly, but compared with the model control group. There was no statistical difference between the groups.

Embodiment 2

[0064] Collect the 24h urine of each animal 21 days after modeling and 7, 14, 21, 28... 56 days after administration, measure the volume, measure the protein content in the urine with the CBB method, calculate the total amount of urine protein, and use mg / 24h said. The results are shown in Table 2:

[0065] Table 2 Administration 8 weeks on the impact of model rat urine protein

[0066]

[0067] Compared with the control group: ▲ / ▲▲ P<0.05 / 0.01; compared with model group: * / **P<0.05 / 0.01

Embodiment 3

[0069] Fasting without food and water for 12 hours after the last administration, after anesthetizing the animal, 4ml of blood was taken from the femoral artery in a heparin anticoagulant tube, and the whole blood viscosity was measured with an MVIS-2015 automatic hemorheometer (results are shown in Table 3); The blood was collected in a 5mL centrifuge tube, centrifuged at 4°C and 4000rpm for 10min, the serum was separated, and the serum levels of TP, ALB, GLO, Cre, BUN, TC, TG, AST, and ALT were measured with an automatic biochemical analyzer (results are shown in Table 4) , and determine NO, SOD, MDA content according to kit method. The results are shown in Table 5:

[0070] The impact of table 3 on model rat hemorheology ( mPa.s)

[0071]

[0072]

[0073] Compared with the control group: ▲ / ▲▲ P<0.05 / 0.01; compared with model group: * / **P<0.05 / 0.01

[0074] It can be seen from Table 3 that compared with the normal control group, the high shear (200s -1 ), middle...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, in particular to a new application of scutellarin, and provides the application of the scutellarin in preparing medicine for reducing pathological changes of kidney tissue and the application of the scutellarin in preparing medicine for treating nephritis. The new application of the scutellarin is proved by experiments to show that the intragastric administration is continuously performed on nephritis model rats with the scutellarin in the dose of 20 mg / kg and 40 mg / kg for eight weeks, the proteinuria of the model animals can be obviously reduced, hypoproteinemia, hyperlipidemia and the hypercoagulable state of blood can be corrected, the serum lipid peroxidation product content of the model rats can be lowered, the expression of TNF-alpha in the kidney tissue can be inhibited, and a protection effect on the kidney tissue and a good improvement effect on the kidney function are achieved; in addition, the maximum dose of intragastric administration on the rats is equal to and more than 18 g / kg, and obvious acute toxicity reaction and death do not occur on the animals.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the new application of scutellarin aglycon. Background technique [0002] Nephritis is an inflammatory lesion caused by pathogenic microorganisms invading the renal pelvis, renal interstitium and renal parenchyma. After different antigenic microorganisms infect the human body, different antibodies are produced, which combine to form different immune complexes, which are deposited in different parts of the kidney, resulting in pathological damage. With the development of society, the change of people's lifestyle, dietary structure and environment, the incidence of kidney disease has a clear upward trend. The incidence of chronic kidney disease in adults in my country is about 8% to 11%. The complexity of the etiology and pathogenesis of nephritis determines the diversity of clinical manifestations, which brings certain difficulties to the diagnosis and symptomatic treatment of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P13/12A61P3/06A61P3/00A61P7/02A61P29/00A23L1/30
Inventor 刘一丹杨旭娟尚建华张伟
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com